Precipio Announces Q4 and year-end 2025 Shareholder Update Call
Rhea-AI Summary
Precipio (NASDAQ: PRPO) will hold a Q4 and year-end 2025 shareholder update call on April 2, 2026 at 5:00 PM ET. The call will cover updates on the company’s core businesses and allow advance questions by email to investors@precipiodx.com.
Dial-in is 646.307.1865; a replay will be available about 24 hours after the call on the company’s Investors page.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed momentum: scanner data flags 4 names with 2 up and 2 down (median move about -4.1%), while other listed peers range from about -7% to +9% on the day.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Clinical study data | Positive | +3.3% | Joint study validated Bloodhound BCR::ABL1 assay performance and sensitivity. |
| Feb 25 | Prelim 2025 results | Positive | -3.9% | Reported 2025 revenue growth to $24.0M with positive adjusted EBITDA and cash flow. |
| Jan 15 | Balance-sheet cleanup | Positive | +0.0% | Repaid $1.1M advance, reduced long-term debt and eliminated financing warrants. |
| Dec 05 | Conference presentation | Positive | -2.4% | Announced ASH presentation highlighting BCR::ABL1 assay performance in 895 samples. |
| Dec 04 | Security incident | Neutral | -3.1% | Reported limited unauthorized access to cloud storage with no material operational impact. |
Recent news has generally been positive, but 4 of the last 5 items coincided with flat-to-negative next‑day moves, suggesting a tendency for muted or contrary short-term reactions.
Over the last several months, Precipio has focused on strengthening operations and showcasing its technology. A Jan 15, 2026 update highlighted substantial balance-sheet cleanup and reduced long‑term debt. On Feb 25, 2026, the company reported unaudited $24.0M 2025 revenue, up 30% year‑over‑year, with positive adjusted EBITDA and operating cash flow. A joint BCR::ABL1 assay study with Memorial Sloan‑Kettering was featured in December and again in a Mar 10, 2026 publication. The current shareholder call notice fits into this pattern of ongoing operational and scientific updates.
Market Pulse Summary
This announcement sets the date and time for Precipio’s Q4 and year‑end 2025 shareholder update call on April 2, 2026 at 5:00 PM ET. It follows recent disclosures of revenue growth, positive EBITDA, and balance‑sheet strengthening, as well as clinical data on the Bloodhound BCR::ABL1 assay. Investors tracking the story may focus on the upcoming call for detailed 2025 financials, cash‑flow trends, and progress across core businesses, as well as any updates versus prior preliminary figures.
AI-generated analysis. Not financial advice.
Conference Call to be held on April 2nd, 2026 at 5:00 PM EST
NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses.
The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call.
Listeners interested in submitting questions in advance should email their questions to investors@precipiodx.com and management will do its best to address those questions during the call.
A replay of the call will be available approximately 24 hours after the call and may be accessed via the Investors page on Precipio's website, https://www.precipiodx.com/investors/.
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523
FAQ
When is Precipio's (PRPO) Q4 and year-end 2025 shareholder update call?
How can investors join the Precipio (PRPO) April 2, 2026 conference call?
Can shareholders submit questions before the Precipio (PRPO) April 2, 2026 call?
Will Precipio (PRPO) provide a replay of the April 2, 2026 shareholder call?
What topics will Precipio (PRPO) cover on the April 2, 2026 update call?
